iTeos to shut down following $2bn GSK-partnered TIGIT asset failure
iTeos will look to distribute its cash reserves to shareholders, along with proceeds raised from selling pipeline assets.
Business & Regulation
HHS sets “most favoured nation” pricing targets for drug makers
Regeneron buys bankrupt 23andMe for $256m
Novo Nordisk’s CEO to step down as weight loss market share plummets
FDA biosimilar approvals set for record-breaking year amid US pricing reforms
Abeona secures cash runway with $155m priority review voucher sale
Q1 earnings pulse check: companies tentative on pharma-specific tariffs
Biogen’s Q1 revenue soars past estimates as rare disease pivot pays off
